Dr. Boland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
100 Campus Dr
Unit 108
Scarborough, ME 04074Phone+1 207-303-3300Fax+1 207-250-2139
Summary
- Patrick Boland, MD, is an Oncologist based in Maine. He completed his medical education at the University of Minnesota Medical School in 2017, followed by a residency in Internal Medicine at NYU Grossman School of Medicine from 2017 to 2018. Dr. Boland has several publications in his field, with topics ranging from the outcomes of second-line therapies in patients with metastatic de novo and treatment-emergent neuroendocrine prostate cancer to the risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis. These works have been recognized and cited by other publications multiple times.
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2017 - 2018
University of Minnesota Medical SchoolClass of 2017
Certifications & Licensure
FL State Medical License 2023 - Present
ME State Medical License 2023 - 2026
NH State Medical License 2023 - 2025
NC State Medical License 2021 - 2023
NY State Medical License 2019 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsOutcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.Corbin J Eule, Junxiao Hu, Sulaiman Al-Saad, Katharine Collier, Patrick Boland
Clinical Genitourinary Cancer. 2023-08-01 - 6 citationsDistinct IDH1/2-associated Methylation Profile and Enrichment ofandMutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma.Josephine Kam Tai Dermawan, Khedoujia Nafa, Abhinita Mohanty, Yingjuan Xu, Ivelise Rijo
Cancer Research Communications. 2023-03-01 - 26 citationsRisk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.Elizaveta Efuni, Samuel Cytryn, Patrick Boland, Timothy B. Niewold, Anna C. Pavlick
Journal of Clinical Rheumatology. 2021-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
